T
Todd R. Golub
Researcher at Harvard University
Publications - 454
Citations - 234100
Todd R. Golub is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Gene expression profiling. The author has an hindex of 164, co-authored 422 publications receiving 201457 citations. Previous affiliations of Todd R. Golub include Rush University Medical Center & Boston Children's Hospital.
Papers
More filters
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer
Trudy G. Oliver,Kim L. Mercer,Leanne C. Sayles,James R. Burke,Diana Mendus,Katherine S. Lovejoy,Mei-Hsin Cheng,Aravind Subramanian,David Mu,Scott Powers,Denise G. Crowley,Roderick T. Bronson,Charles A. Whittaker,Arjun Bhutkar,Stephen J. Lippard,Todd R. Golub,Juergen Thomale,Tyler Jacks,E. Alejandro Sweet-Cordero +18 more
TL;DR: In this paper, the dynamics of response to a mainstay chemotherapeutic, cisplatin, in multiple mouse models of human non-small-cell lung cancer (NSCLC) was examined.
Journal ArticleDOI
A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility
Jennifer L. Shepard,James F. Amatruda,Howard M. Stern,Aravind Subramanian,David Finkelstein,James Ziai,K. Rose Finley,Kathleen L. Pfaff,Candace Hersey,Yi Zhou,Bruce A. Barut,Matthew L. Freedman,Charles Lee,Jan M. Spitsbergen,Donna Neuberg,Gerhard J. Weber,Todd R. Golub,Jonathan N. Glickman,Jeffery L. Kutok,Jon C. Aster,Leonard I. Zon +20 more
TL;DR: The findings show that zebrafish screens can uncover cancer pathways, and demonstrate that loss of function of bmyb is associated with cancer.
Journal ArticleDOI
An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
Benjamin L. Ebert,Naomi Galili,Pablo Tamayo,Jocelyn Bosco,Jocelyn Bosco,Raymond H. Mak,Raymond H. Mak,Jennifer Pretz,Jennifer Pretz,Shyam K. Tanguturi,Christine Ladd-Acosta,Richard Stone,Richard Stone,Todd R. Golub,Azra Raza +14 more
TL;DR: It is indicated that lenalidomide-responsive patients have a defect in erythroid differentiation, and a strategy for a clinical test to predict patients most likely to respond to the drug is suggested.
Journal ArticleDOI
Humanized mice with ectopic artificial liver tissues.
Alice A. Chen,David Thomas,Luvena L. Ong,Robert E. Schwartz,Todd R. Golub,Sangeeta N. Bhatia +5 more
TL;DR: M mice with HEALs are used to predict the disproportionate metabolism and toxicity of “major” human metabolites using multiple routes of administration and monitoring to enable manufacturing of reproducible in vivo models for diverse drug development and research applications.
Journal ArticleDOI
Proteomic and Genetic Approaches Identify Syk as an AML Target
Cynthia K. Hahn,Jacob E. Berchuck,Kenneth N. Ross,Rose M. Kakoza,Karl R. Clauser,Anna C. Schinzel,Anna C. Schinzel,Linda Ross,Ilene Galinsky,Tina N. Davis,Serena J. Silver,David E. Root,Richard Stone,Daniel J. DeAngelo,Martin Carroll,William C. Hahn,William C. Hahn,Steven A. Carr,Todd R. Golub,Todd R. Golub,Todd R. Golub,Andrew L. Kung,Kimberly Stegmaier,Kimberly Stegmaier +23 more
TL;DR: This report integrated proteomic and RNAi-based strategies to identify their off-target, anti-AML mechanism and genetic and pharmacological inactivation of Syk with a drug in clinical trial for other indications promoted differentiation of AML cells and attenuated leukemia growth in vivo.